Multiple Myeloma

A phase 2 trial shows promise of the daratumumab/ixazomib combination in frail and elderly patients with multiple myeloma who are treated in the relapsed setting when given without dexamethasone.

Patients receiving daratumumab, lenalidomide, and dexamethasone in the first line saw better overall survival than those who waited and received second-line daratumumab-based regimens for transplant-ineligible newly diagnosed multiple myeloma.

Luciano Costa, MD, PhD, spoke about which abstracts he wants to see most at ASH 2021.

Thomas G. Martin, MD, spoke about the previously reported results of the CARTITUDE-1 study in patients with relapsed or refractory myeloma ahead of the 2021 ASH Annual Meeting.

Thomas G. Martin, MD, spoke about the abstracts regarding B-cell maturation antigen–targeted treatments he’s excited to see presented at ASH 2021.

Nina Shah, MD, touched on important abstracts being presented at the 2021 American Society of Hematology Annual Meeting.

Thomas G. Martin, MD, spoke about different abstracts to be presented at ASH 2021.

Nina Shah, MD, highlights some of the major takeaways in multiple myeloma from the 2021 European Hematology Association Congress.

Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.

Panobinostat, which received accelerated approval by the FDA in February 2015 for patients with previously treated multiple myeloma, has had its indication withdrawn in the United States.

A combination of daratumumab, hyaluronidase-fihj, carfilzomib, and dexamethasone has been approved by the FDA for the treatment of relapsed/refractory multiple myeloma.

Concluding their discussion on newly diagnosed multiple myeloma, expert panelists consider treatment options for patients with high-risk disease.

Shared insight on the evolving treatment landscape of transplant-ineligible newly diagnosed multiple myeloma.

Patients with relapsed/refractory myeloma continued to experience durable and efficacious responses after treatment with ciltacabtagene autoleucel.

Following discussion with the FDA, INN melphalan flufenamide has been withdrawn from market in the United States based on data from the phase 3 OCEAN study.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to highlight key lessons that COVID-19 pandemic taught him.

After reviewing the case of a patient with transplant-eligible newly-diagnosed multiple myeloma, experts consider optimal selection of first-line treatment.

After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.

Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic affected his work and how they adapted.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.

Patients with high-risk smoldering myeloma who were treated with carfilzomib, lenalidomide, and dexamethasone and lenalidomide maintenance experienced an improvement in minimal residual disease–negative complete response and could have delayed end-organ disease.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.

A panel of hematologists/oncologists conclude a discussion about transplant-ineligible multiple myeloma (MM) by reacting to current treatment gaps that need to be addressed.

Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.

In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.

Recommendations when talking with patients with transplant-ineligible multiple myeloma (MM) who request to stop receiving treatment.

The phase 1b/2 CARTIRUDE-1 study found deep and durable responses, along with a tolerable safety profile with the recommended phase 2 dose of ciltacabtagene autoleucel for patients with relapsed or refractory multiple myeloma.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss key implications from the phase 2 MASTER trial, utilizing daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.